Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004%
compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension
(OH). The study structure is a parallel design. The patients will receive treatment for 12
The International Collaborative Exfoliation Syndrome Treatment Study
Purpose: To determine the efficacy of treatment with latanoprost in combination with
pilocarpine versus timolol or timolol/dorzolamide fixed combination (Timoptic or Cosopt) in
eyes with XFS and elevated intraocular pressure (IOP).
Methods: This is a randomized, open-label study to test the hypothesis that improving both
pressure-dependent and pressure-independent aqueous outflow and minimizing iridolenticular
friction will interfere with the progression of XFS, allow improvement in trabecular
function, and be more effective over time than simply reducing aqueous formation.
Randomization was performed across the centers, per patient rather than per eye to avoid any
crossover effect caused by aqueous suppressants. Group I was treated with latanoprost and
pilocarpine, both in the evening, and Group II with Timolol or Cosopt b.i.d. Only one eye
per patient was randomized. Patients were followed for 2 years with assessment of IOP,
visual field progression, tonographic outflow coefficient and trabecular pigmentation at the
6:00 and 12:00 position.
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.